Adaptive Biotechnologies (NASDAQ:ADPT) Insider Harlan Robins Sells 100,000 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $17.37, for a total value of $1,737,000.00. Following the completion of the sale, the insider owned 1,412,058 shares in the company, valued at approximately $24,527,447.46. This represents a 6.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Trading Down 2.6%

NASDAQ:ADPT opened at $16.78 on Thursday. The stock has a market capitalization of $2.69 billion, a P/E ratio of -50.85 and a beta of 2.15. Adaptive Biotechnologies Corporation has a 1 year low of $9.96 and a 1 year high of $20.76. The firm has a 50 day moving average of $14.72 and a 200-day moving average of $15.59.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.Adaptive Biotechnologies’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.20) EPS. As a group, analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

More Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Adaptive Biotechnologies and set a $22 price target, implying meaningful upside from recent trading levels.
• Positive Sentiment: The company priced an upsized $300 million offering of 0% convertible senior notes due 2031, and management said proceeds will help repay the OrbiMed agreement, fund capped-call protection, and support a $25 million share repurchase to reduce dilution.
• Neutral Sentiment: The initial conversion price of about $24.11 per share and capped-call structure may help limit dilution if the stock rises, which could support longer-term sentiment.
• Negative Sentiment: Investors may view the larger convertible issuance as a sign of financing needs, especially since the offering was increased from $250 million to $300 million.
• Negative Sentiment: Insider selling added pressure: Chief Scientific Officer Harlan S. Robins sold 106,160 shares in two recent transactions, and the company’s recent insider activity has consisted entirely of sales.
• Negative Sentiment: A prior report also noted the stock fell after the original convertible-debt plan, suggesting shareholders are sensitive to dilution and capital-structure changes.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC acquired a new position in Adaptive Biotechnologies in the first quarter valued at about $2,117,000. Bank of America Corp DE raised its position in shares of Adaptive Biotechnologies by 52.3% during the first quarter. Bank of America Corp DE now owns 1,227,917 shares of the company’s stock worth $17,043,000 after purchasing an additional 421,645 shares during the period. Amundi bought a new position in shares of Adaptive Biotechnologies during the 1st quarter valued at about $148,000. California State Teachers Retirement System lifted its holdings in shares of Adaptive Biotechnologies by 28.4% during the 1st quarter. California State Teachers Retirement System now owns 143,658 shares of the company’s stock valued at $1,994,000 after purchasing an additional 31,782 shares in the last quarter. Finally, SummitTX Capital L.P. acquired a new position in shares of Adaptive Biotechnologies in the 1st quarter valued at approximately $4,409,000. 99.17% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ADPT has been the topic of several recent research reports. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. TD Cowen boosted their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. BTIG Research reaffirmed a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday. JPMorgan Chase & Co. cut their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.